Prosecution Insights
Last updated: April 19, 2026

Examiner: KASSA, TIGABU

Tech Center 1600 • Art Units: 1619

This examiner grants 36% of resolved cases

Performance Statistics

36.3%
Allow Rate
-23.7% vs TC avg
763
Total Applications
+28.7%
Interview Lift
1711
Avg Prosecution Days
Based on 705 resolved cases, 2023–2026

Rejection Statute Breakdown

0.8%
§101 Eligibility
12.4%
§102 Novelty
62.8%
§103 Obviousness
15.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18256943 MINI-TABLET DOSAGE FORM OF A VIRAL TERMINASE INHIBITOR AND USES THEREOF Non-Final OA Merck Sharp & Dohme LLC
18073958 Shampoo Composition Comprising Gel Matrix and Histidine Non-Final OA The Procter & Gamble Company
18538022 BIODEGRADABLE COMPACTED FORMULATIONS AND METHODS OF USE AND MANUFACTURE THEREOF Non-Final OA Purdue Research Foundation
18516295 Softgel Capsule and Method of Marking a Softgel Capsule Non-Final OA R.P. Scherer Technologies, LLC
18208635 ENTERIC BISACODYL SOFTGEL CAPSULE Non-Final OA R.P. Scherer Technologies, LLC
19169817 USE OF VARENICLINE FOR TREATING OCULAR CONDITIONS Final Rejection Oyster Point Pharma, Inc.
18399677 ENHANCED NITRATE COMPOSITIONS AND METHODS OF USE Non-Final OA ThermoLife International, LLC
18399668 ENHANCED NITRATE COMPOSITIONS AND METHODS OF USE Non-Final OA ThermoLife International, LLC
18399465 ENHANCED NITRATE COMPOSITIONS AND METHODS OF USE Non-Final OA ThermoLife International, LLC
18399664 ENHANCED NITRATE COMPOSITIONS AND METHODS OF USE Non-Final OA ThermoLife International, LLC
17941129 FILM-COATED GRANULE, PHARMACEUTICAL PREPARATION CONTAINING THE SAME, AND MANUFACTURING METHODS THEREOF Non-Final OA SAWAI PHARMACEUTICAL Co., Ltd.
17946610 POLYELECTROLYTE-LAYER FORMING BLOCK COPOLYMERS AND COMPOSITIONS AND USES THEREOF Non-Final OA Rhodia Operations
16929565 SEED COATINGS, COATING COMPOSITIONS AND METHODS FOR USE Non-Final OA RHODIA OPERATIONS
17293621 SURFACTANT-STABILIZED FLUID INTERFACE AND DISPERSION COMPRISING ONE OR MORE DROPLETS HAVING A SURFACTANT STABILIZED FLUID INTERFACE Non-Final OA MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
17530559 PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF Non-Final OA Boehringer Ingelheim International GmbH
18691949 ANTI-AGING AGENT, COSMETIC PRODUCT, WET TOWEL, AND HYGIENE PRODUCT Non-Final OA VB JAPAN TECHNOLOGY CO., LTD.
18195239 REACTIVE GRANULATION OF CALCIUM CITRATE MALATE, DICALCIUM MALATE, AND DIMAGNESIUM MALATE Final Rejection Balchem Corporation
18431461 STABILISED COMPOSITIONS Non-Final OA Rumin8 Pty Ltd
17340132 Consumer Products with Improved Aesthetics Final Rejection INTERNATIONAL FLAVORS & FRAGRANCES INC.
18256752 SUSTAINED RELEASE FORMULATIONS OF CRYSTALLINE DRUGS Non-Final OA QUEEN MARY UNIVERSITY OF LONDON
18267459 METHOD FOR PREPARING PHARMACEUTICAL FORMULATION OF TABLET CONTAINING TRIZOLOPYRAZINE DERIVATIVE AS AN ACTIVE INGREDIENT Non-Final OA ABION Inc.
18038781 ORAL SOLID PREPARATION COMPRISING N2-{[1-ETHYL-6-(4-METHYLPHENOXY)-1H-BENZIMIDAZOL-2-YL] METHYL}-L-ALANINAMIDE Final Rejection ALPHANAVI PHARMA INC.
18030541 STABLE ORAL DISPERSIBLE FORMULATION FOR EPINEPHRINE Final Rejection Catalent U.K. Swindon Zydis Limited
17623576 LEVODOPA POLYMERIC CONJUGATES, FORMULATIONS THEREOF, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE Final Rejection DYNAMIC BIOLOGICS INC.
18008421 NANOPARTICULATE COMPOSITION Non-Final OA Algiax Pharmaceuticals GmbH
17793324 VETERINARY ANTI-PROLACTIN COMPOSITION FOR RUMINANTS USED BY INTRAMAMMARY ADMINISTRATION Final Rejection Ceva Santé Animale
17920690 MODIFIED RELEASE PHARMACEUTICAL FORMULATION COMPRISING HYDROXYPROPYL CELLULOSE Non-Final OA HERCULES LLC
17995768 Compositions and Methods For Blood-Brain Barrier Delivery Non-Final OA Aliada Therapeutics, Inc.
16628399 IMPLANTABLE DEVICE Final Rejection Biotyx Medical (Shenzhen) Co., Ltd.
17843137 CROSSLINKED PLA-BASED COPOLMERS Non-Final OA Pendant Biosciences, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month